Abstract
Introduction: Advanced outbreak analytics played a key role in governmental decision-making as the COVID-19 pandemic challenged health systems globally. This study assessed the evolution of European modelling practices, data usage, gaps, and interactions between modellers and decision-makers to inform future investments in epidemic-intelligence globally. Methods: We conducted a two-stage semi-quantitative survey among modellers in a large European epidemic-intelligence consortium. Responses were analysed descriptively across early, mid-, and late-pandemic phases. Policy citations in Overton were used to assess the policy impact of modelling. Findings: Our sample included 66 modelling contributions from 11 institutions in four European countries. COVID-19 modeling initially prioritised understanding epidemic dynamics. Evaluating non-pharmaceutical interventions and vaccination impacts became equally important in later phases. 'Traditional' surveillance data (e.g. case linelists) were widely used in near-real time, while real-time non-traditional data (notably social contact and behavioural surveys), and serological data were frequently reported as lacking. Data limitations included insufficient stratification and geographical coverage. Interactions with decision-makers were commonplace and informed modelling scope and, vice versa, supported recommendations. Conversely, fewer than half of the studies shared open-access code. Interpretation: We highlight the evolving use and needs of modelling during public health crises. The reported missing of non-traditional surveillance data, even two years into the pandemic, underscores the need to rethink sustainable data collection and sharing practices, including from non-profit providers. Future preparedness should focus on strengthening collaborative platforms, research consortia and modelling networks to foster data and code sharing and effective collaboration between academia, decision-makers, and data providers.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/chiara-poletto/Modelling-practices/
Funding Statement
The work was supported by EU grant 874850 MOOD and is registered as MOOD publication 133. The contents of this publication are the sole responsibility of the authors and do not necessarily reflect the views of the European Commission. S.D. acknowledges support from the Fonds National de la Recherche Scientifique (F.R.S.-FNRS, Belgium; grant #F.4515.22), from the Research Foundation, Flanders (Fonds voor Wetenschappelijk Onderzoek, Vlaanderen, FWO, Belgium; grant #G098321N), and from the European Union Horizon 2020 projects MOOD (grant agreement #874850) and LEAPS (grant agreement #101094685). W.V.B. acknowledges funding from the Belgian Science Policy research grant BE-PIN (TD/231/BE-PIN) and is a member of the Outbreak Research Team (ORT) of the Institute of Tropical Medicine. This ORT is financially supported by the Department of Economy, Science and Innovation of the Flemish government. S.L.v.E. acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking. V.C. acknowledges support from EU Horizon 2020 grant MOOD (H2020-874850), Horizon Europe grant ESCAPE (101095619), ANR grant DATAREDUX (ANR-19-CE46-0008-03). M.U.G.K. acknowledges funding from The Rockefeller Foundation (PC-2022-POP-005), Google.org, the Oxford Martin School Programmes in Pandemic Genomics & Digital Pandemic Preparedness, European Union's Horizon Europe programme project E4Warning (#101086640), Wellcome Trust grants 303666/Z/23/Z, 226052/Z/22/Z & 228186/Z/23/Z, the United Kingdom Research and Innovation (#APP8583), the Medical Research Foundation (MRF-RG-ICCH-2022-100069), UK International Development (301542-403), the Bill & Melinda Gates Foundation (INV-063472) and Novo Nordisk Foundation (NNF24OC0094346). C.P. acknowledges funding from Cariparo Foundation through the program Starting Package. The funders had no role in the manuscript. The authors declare no conflicts of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos